George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Barder states in presentation that they are not taking sales from products like viagra or Cialis, they are creating a new market with new customers. so if that’s the case why would these companies aggressively target Eroxon during launches to hamper sales?? They may have, when product was first released but based on this info would be a waste of money wouldn’t it? He just likes the words commercially sensitive, has to get those words in as many times as he can!😂
Not sure what more the investors were expecting at this release of results, some magic words perhaps to send the SP to lunar sphere? I guess that is why Barder stared out of the window looking totally disinterested. Wonder what is was watching out there.
Launches are property of the distributors, who will have their own pre-launch news release and duty to their own share holders.
FUM revenue is predominately dependent upon royalty payments.
It has always been about the US launch, which could come at anytime from now to early 2025.
Unlike other AIM situations, where waiting for oil discovery results, gold mining strikes or partnership deals etc.. FUM has a working, proven product awaiting to hit the sales market. There is no ambiguity regarding it's credibility.
People who are anxious about the SP are the ones waiting to sell up on any decent SP rise others are in for the dividends.
bolo end of year report. wheres the units sold? wheres the blowing ones trumpet., jeeez that was some back of *** packet maths report. stupid. they have a killer market blowing product and...... smeg all?? dont get it, what arw futura doing? hand that product here, i'll get that sp up! damn it. joke, utter joke.
Worth noting parts of the summary of analyst coverage today, via Proactive Investors:
“Futura Medical PLC's clinically proven, topical gel treatment for erectile dysfunction, Eroxon, offers a "significant and still underappreciated opportunity", said Stifel as it initiated coverage on the stock with a 'buy' rating.
The shares offer "a compelling investment opportunity" as the US launch approaches, said the brokerage, setting a 125p share price target.
The initiation note also highlighted the ED market is large at $3.5 billion annually and still growing, with Eroxon's key differentiating features versus current treatments being rapid onset of action, cleaner safety profile and unique off-the-shelf status.
Future generated first revenue last year of £3.1 million and Stifel forecasts this rising to £9.2 million this year and £15.8 million in 2025, when it forecasts a first pre-tax profit.
House broker Liberum's estimates are for £10 million sales this year and £18 million in 2025.
Stifel forecasts peak worldwide sales of $364 million for Eroxon in 2029, though a chunk of that will be absorbed by distributors and other middlemen.
The majority of expected sales are seen derived from the US market, around $223 million (£176m) in that year, with Europe peaking at $117 million by 2028.
"Importantly, Futura is fully funded through to profitability, supported by UK and European revenues, with US royalty revenues expected in FY25.
"We note that profitability might come sooner than our current expectations if there is an earlier-than-anticipated US launch in FY24, triggering an estimated $5m launch milestone in the process."
Liberum noted that 2023 revenues had been pre-announced and that gross profit was in line with expectations and that the 57% gross margin "should be indicative of steady state margins.”
News of Eroxon’s launch in the US could arrive at any time, and Futura’s shares gap up very substantially. Those ‘investors’ waiting in the wings for ‘tablets of stone’ from Haleon / Futura can expect to find themselves chasing after a ship that has left port, and - like cruise ship passengers who have missed their ship - will have to rejoin elsewhere, at a much higher share price, reducing their possible return.
Investment is about prospecting through mountains of, often, useless information, recognising and joining the dots of the really key information. It’s a skill, and part of that skill is having patience. As well, part of that skill is recognising the limits of virtually any investor operating on the right side of the law to consistently successfully ‘market time’ buying and selling.
Today’s RNS was disappointing. The investor meet overwhelmingly so. But the FD did provide the clue to the exact moment when Futura will become profitable. That’s worth staying invested for, I think.
Yep, price went below 37p so I topped up too and hit snooze on the alarm.
Completely agree,weareallguessing. i also topped up this afternoon when the s/p appeared to have stabilised.when you consider the likely news flow over the next 12 months or so,it is very hard to imagine the s/p staying at this low level for long.aimo.
Agree. Lots of unrealistic expectations around this. Most blue sky jam tomorrow companies come to nothing. We are really lucky here to have something which is now selling well and has a real future and a company that will not need further fund raising/ share dilution. It takes on average seven years to get a product to market. We are there. I was happy to top up today.
Disappointed but expected let’s face it, and Barder it’s not that you look miserable (from proactive video his words). It’s the cheesy smirk & the fact that when you speak we never get an answer just like a politician that we dislike DYOR! His likeness to a politician is unreal, when the company is bought out & he’s moved on, he has a calling!
do not be put off by the **** management, they are usually lethargic anyway and this product's success hasn't helped that. went into the biggest boots in the city yesterday and asked asked one of the girls behind the tills about the product again (after 1 year) i picked her because i recognised her face from before. asked her straight up if it works and if it's been selling regularly, she told me that yes it sells regularly, it was a vehement response in the end because i deliberately challenged what she said in a couple of ways. i have now heard this from two big boots outlets and this is about a year after hitting the market. and then today we get this. i honestly thought they had learned their lesson with regards to pr, but obviously not.
Does anybody on this forum know of somebody who has received an NHS prescription for Eroxon ?
On the next results we should see lots of sales to the NHS. Then have news on USA roll out and that is when the real money rolls in. With future erectile dysfunction meds are worth $4B over the next few years, 20% of that is huge. Great time to buy in for the huge rise to come and of course Dividends.. Great buy guys. Now buy the FFFFINg dip
I am not asking anyone to try a product where they do not need to, I for one never ever would need to use such a product but did so in the interests of being an investor. Even at my great age and sparing the details it defintely does change the experience for the better - imvho there are more legs in this product than just ED...hence all the comments about R&D today and building a wider product platform. I am a population of one in terms of an experience feedback, so you can all take that with a pinch of salt. But I do like the idea of making something along these lines available for women.
Nothing of nothing is nothing!!! Profit is key to any investment! obvious! FUM's distributors are in a period of growth & smoothing out any logistical things along the way. As long time FUMsters will no it has been an incredibly slow journey of ups & downs (SP included). You have to admire FUM's determination to get this product to market. That doesn't happen unless founder & distributors are in alignment that the product has some legs. You certainly don't get deals such as Haleon on a whim til end of 2029. I was involved in building a dealer network for 5 years across the world & it does take TIME, TIME & MORE TIME, it is what it is. For the record anyone saying I'm deluded needs to understand business & distribution/channels. They don't build there selves. Firstly network is built on a product that does what it says. price protection. expansion on territories. Education. Over time these bumps get ironed out. Do you not think Viagra had all these challenges??!! THEY DID & MORE!. & look at what market they captured & profited from into the billions & billions year on year. In actual fact it is deluded to think that from point of launch of Eroxon that things could be any further forward. Milestones that have already happened are Hugh & continually moving forward. Lets not be negative about any projections Barder has already estimated. Its not an exact science. Lets say he or someone did project some figures etc... then when they are not met, your shot down, dammed if you do!!!! The product does what it says for 60% of users, that has to be the key to a future of massive growth & profits. Not to mention the users that don't suffer ED & want to experiment. Whether people like it or not Eroxon is just not quite there yet! in terms of profit, but 100% will be. Those that can't see that & put forward such negative comments, sell up & ship out. But I challenge you to find another stock that has this potential, at this current time, is sitting at the SP it is, massively under valued. I think all posting negative comments on this forum are ironically still invested, but just very frustrated that their bank balance isn't hitting the roof. This investment will come good for the worthy, the worthy being those that sit...wait...wait some more. wait some more...then wow its rising!
Grateful to all those knockers who have enabled me to invest my ISA money for 2024/5 with more FUM shares than I anticipated this morning.
If those sellers were genuine investors then clearly they hadn’t done their homework properly and don’t understand how Futura operates through the Distributor network and whose wishes as to client confidentiality are paramount..
For those seeking “ instant gratification “ may I draw your attention to the 3 Day Aintree Meeting
starting tomorrow with the Grand National on Saturday.
Who knows you might make enough to buy some more Futura shares to put in your ISA !
Good luck all long term FUMSTERS.
Arturo.
I've not posted on here before, but I also think this is good time to top up as well (which I have done this morning). I've held shares for sometime! Everyone seems to want instant results. This is a new product, and it will take time to setup, manufacture and then distribute the product. The company is also learning as it goes along. I managed to listen to some of the presentation and it was said that the company has enough cash flow to see them through to probability but for some reason that is not being said on this board? That is a huge plus meaning no more fund raises for investors.
I 100% agree with Bottom Feeder.
It was a major opportunity missed today and this SP never fails to disappoint. Anyone saying we need to be more patient is deluded and can't be a true LTH.
How can this reach 80p after the EU granted the CE Mark to MED3000, but three years later after multiple launches across the world, is only at 36p (and trending down).
Wage and salaries cost 2,284,000 / 12 staff = 190k average salary.
One thing I did notice they have just over £1.1 million for a merger reserve!
'bottom_feeder', in September last year you were saying 'STRONG, STRONG buy' and 'FUM (imho) is now one of the few I actually think will double my investment within a year. So, I'm happy to wait up to 12 months to make £50k+ profit. And shall be topping up regularly.'
And yet here you are, not 7 months later, losing the plot and applying a 'strong sell' recommendation. Quite the turnaround.
FUM can't provide what they are binded to protect! Partners will do this & allow flow of more data as time unfolds. Sorry people but I'm sure what you were expecting Barder to say. He may have seemed a bit distracted, that's probably because his hands are tied & he can only say so much. Distributors have strict data protection, to protect their supply channels. Keep saying it but times key here.....
All providing negative comments, please do...as the more the SP should come down the better....as I will be topping up as much as possible. It takes time & patience to build a brand. To many knocking FUM. They have done incredibly well to get to this point. What's not to be excited about. If you want quick over night returns, invest in something else. FUM are dammed if they do dammed if they don't in some opinions. If all the launches to date is not doing it for you...sell. This product is going from strength to strength. But all said, the only thing that counts is profit! They've remained true...USA Launch = profit! higher SP quite simple for me....
RNs statement:
"Futura Medical Chief Executive Officer James Barder said: "I am delighted to be reporting on this landmark set of results..."
Me thinks we werer all watching a different Video. It was nothing short of hugely disappointing. Sorry, you can all say I'm wrong or being negative etc but it's clear that the BOD has no intention of giving Private Shareholders any information to make any form of investment decision.
Simply saying their hands are commercially or legally tied etc is passing the buck.
And trying to persuade anyone to simply "bear with us" is NOT the statement of a confident, professional company approach.
We don't even have any idea of what the future product rangee is or what they are actually working on. All hush hush, can't give away infor to competitors etc.
This is actually the worst company shareholder presentation I have ever seen - bare none.
Couldn't agree more that it was an incredibly frustrating presentation.
Forstly, Kames Barder' body language of continuously looking out the window while speaking was very off-putting as it gave the impresioon that he actually wasn't interested (yes I know he's simply 'contemplating' his responses etc) but it gives a very negative impression.
THe biggest issue is they would not give any idea of future projected income. Yes we all know its not possible for them to disclose commercial information etc. But they only gave 'projected' figures for the Us market then left it to us to try to figure out what that means for the entire world marlet (excluding China of course).
FUM have stated that tthey beleivee they will be "Net Positive" by 2025. Yet were unabel to give a projected gross income figure to support this statement.
They MUST have alculated their projected income stream againsst future spend to arrive at this 'formal' Net-Positive statement. SO why can't they provide their projected income estimates?
As an LTI I am very disappointed in thhis presentation as it gives me absolutely no clue as to the future potential revenue or anything else.
It wa just a "wash-out".
I'm not surprised the SP has dropped so savagely by over 16%
Sorry, but had to put a "Strong Sell" for today's useless presentation.
Presentation was as expected for me. Having worked at the sharp end on a product with similar scale out, all is moving in the right direction. Partners of FUM will protect their privacy to launches & other data. This investment in IMO remains up there... the best I have. As I have said before this is a slow burn while all partners world over, come in to alignment with this product. A Brand takes minimum 3 years to build. USA will 100% be the catalyst for profit & SP lift. To many people being negative. Its still early days since first launch. Its all building. All going on in the background. Lots of hard work. It will come good. US will be all over this at launch. Haleon will sky rocket this product! Hang in there
So, there it is. Nowt new from Futura.
Or did the RNS alone tell the whole story?
Fast forward to the investor call.
Lots of disappointing “no news”: News on product extensions promised last September did not materialise. China, which accounts for c 1/5th of global population, was another area without news. Futura declares that its strategy has shifted to focus on sexual health, begging the question - no answer provided - what will happen to its cannabidiol assets. Will they be sold?
Gold prospecting among all this and more of disappointing material, for me the golden nugget was the clarity of realising that the Big Bang moment in Futura’s share price will be Haleon announcing the launch of sales in the US. The FD stated more than once that when Haleon launches sales in the US, Futura will become profitable. At a stroke, red ink will become black ink. The US launch “expected by early 2025” point in the RNS was explained by the FD as simply a “read across” from Haleon’s February announcement that it planned to launch Eroxon “within the next year”. “Early 2025” is simply a worst case scenario; the best case is well before then.
Nothing else really matters now. Country launches by Cooper and other distributors will be important, but sparklers rather than the explosive firework provided by Haleon launching sales in the US.
At that point, the “keep delivering” mantra of James et al as a response to poor share price performance will, the company expects, turn red ink to black, and thereby create real fruit for long term shareholders.
We just need to remember James’s parting words - “bear with us”.
"The markets are abysmal, too many characters with nanosecond attention spans who need instant gratification"
See it as an opportunity to relieve them of their shares, at a low price.
To me it beggars belief that Futura is saying 'we have one of the largest consumer health companies in the world launching our (FDA approved) product in the U.S. in the next 12 months' and AIM lemmings can only say 'but I want it NOW!!'